Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Priorities for improving drug research, development and regulation

Nature Reviews Drug Discovery volume 12, pages 247–248 (2013)Cite this article

Subjects

Improved R&D models, supported by appropriate regulatory pathways, are needed to provide new drugs with greater efficiency, in a framework that is financially viable for all stakeholders. Here, we present the perspective of the European Federation of Pharmaceutical Industries and Associations on the key areas on which to focus to achieve this.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kola, I. & Bell. J. Nature Rev. Drug Discov. 10, 641–642 (2011).

    Article  CAS  Google Scholar 

  2. Orloff, J. et al. Nature Rev. Drug Discov. 8, 949–957 (2009).

    Article  CAS  Google Scholar 

  3. Breckenridge, A. et al. Nature Rev. Drug Discov. 11, 501–502 (2012).

    Article  CAS  Google Scholar 

  4. European Medicines Agency (EMA) [online], (2010).

Download references

Author information

Authors and Affiliations

  1. Susan R. Forda is Chair of the Scientific, Regulatory and Manufacturing Policy Committee, European Federation of Pharmaceutical Industries and Associations (EFPIA), and is at Eli Lilly and Company, Indianapolis, Indiana 46285, USA.,

    Susan R. Forda

  2. Richard Bergström is Director General of the EFPIA, 108 Rue du Trône, B-1050 Brussels, Belgium.,

    Richard Bergström

  3. Magda Chlebus is Director of Science Policy at the EFPIA, 108 Rue du Trône, B-1050 Brussels, Belgium.,

    Magda Chlebus

  4. Richard Barker is an Independent Advisor to the EFPIA, University of Oxford, New Richards Building, Old Road Campus, Headington, Oxford OX3 7LG, UK.,

    Richard Barker

  5. Peter Høngaard Andersen is Chair of the Research Directors Group, EFPIA, and at H. Lundbeck, Ottiliavej 9, 2500 Valby, Denmark.,

    Peter Høngaard Andersen

Authors
  1. Susan R. Forda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Bergström
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Magda Chlebus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Barker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Høngaard Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Høngaard Andersen.

Ethics declarations

Competing interests

Susan R. Forda is an employee of Eli Lilly and owns shares in Eli Lilly and GlaxoSmithKline.

Richard Bergström receives a salary to represent the interests of pharmaceutical companies.

Magda Chlebus receives a salary to represent the interests of pharmaceutical companies.

Richard Barker is on the boards of the biopharmaceutical companies Celgene and iCo.

Peter Høngaard Andersen is an employee of Lundbeck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forda, S., Bergström, R., Chlebus, M. et al. Priorities for improving drug research, development and regulation. Nat Rev Drug Discov 12, 247–248 (2013). https://doi.org/10.1038/nrd3981

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3981

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research